Progress for our clients in the clinic this week, with Mestag Therapeutics dosing the first patient in their STARLYS clinical trial and STORM Therapeutics to present data on its dose escalation study at ASCO later this month. More good news, as Hansa Biopharma entered a multi-million-Euro licensing agreement with SERB S.A. Bring on the bank […]
Riding the wave of BioEquity, it has been another busy week for Optimum’s clients. Hansa Biopharma, Poolbeg Pharma and Resolution Therapeutics are all taking to the stage across Europe and the US. Optimum’s own Stephen Adams will be chairing a panel at LSX Nordic next week after yet another fascinating Hot Topic – this time […]
With the Anglonordic Life Science Conference last week, BioEquity next week, ASGCT Annual meeting and LSX Nordic Congress around the corner, it is a good time to practice your pitching. Funds are open and now is the time to foster those new and old connections. Read on to discover what has happened this week and […]
A profoundly positive response from Anglonordic attendees with hands shaken, conversations started and potential deals in the works. The main takeaway was the benefit of it being a ‘boutique’ event, meaning everyone could make the most of the 1:1 partnering, pitch presentations, and networking breaks. Keep reading to hear more about what’s been happening this […]
Drum roll… In Vivo’s 2026 Rising Leaders were announced this week and included not one, not two, but five Optimum clients. A huge congratulations to Colleen Acosta of Freya Biosciences, Diana Čekatauskaitė of Lonza’s Synaffix, Reuben Dawkins of Link Biologics, Michelle Morrow of Nucleome Therapeutics, and Javier Nunez-Vicandi of Sofinnova Partners. This list recognises not […]
